QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
NASDAQ:TNYA

Tenaya Therapeutics - TNYA Stock Forecast, Price & News

$2.29
-0.13 (-5.37%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.27
$2.44
50-Day Range
$1.82
$3.36
52-Week Range
$1.73
$22.87
Volume
155,185 shs
Average Volume
187,673 shs
Market Capitalization
$94.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.50

Tenaya Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
977.1% Upside
$24.67 Price Target
Short Interest
Healthy
3.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$6.48 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.72) to ($2.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

284th out of 1,023 stocks

Biological Products, Except Diagnostic Industry

43rd out of 170 stocks

TNYA stock logo

About Tenaya Therapeutics (NASDAQ:TNYA) Stock

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Receive TNYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TNYA Stock News Headlines

Massive Insider Trade At Tenaya Therapeutics
Tenaya Therapeutics Announces Closing of Public Offering
Tenaya Therapeutics Announces Pricing of Public Offering
Tenaya Therapeutics Announces Proposed Public Offering
Tenaya Therapeutics Inc
See More Headlines
Receive TNYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TNYA Company Calendar

Last Earnings
11/10/2021
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/22/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNYA
Fax
N/A
Employees
106
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.67
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+1,100.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-72,720,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.75 per share

Miscellaneous

Free Float
27,208,000
Market Cap
$94.75 million
Optionable
Not Optionable
Beta
1.55

Key Executives

  • Mr. Faraz Ali M.B.A. (Age 49)
    CEO, Sec. & Director
    Comp: $710.77k
  • Dr. Deepak Srivastava M.D. (Age 55)
    Scientific Founder, Chairman of Scientific Advisory Board & Director
    Comp: $18.15k
  • Ms. Leone D. Patterson M.B.A. (Age 59)
    Chief Financial & Bus. Officer
    Comp: $448.55k
  • Dr. Whittemore G. Tingley M.D. (Age 54)
    PH.D., Chief Medical Officer
    Comp: $551.18k
  • Dr. Eric N. Olson Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Dr. Bruce R. Conklin
    Scientific Founder
  • Dr. Saptarsi Haldar M.D.
    Scientific Founder
  • Dr. Sheng Ding
    Scientific Founder
  • Dr. Benoit G. Bruneau Ph.D.
    Scientific Founder
  • Dr. Kee-Hong Kim Ph.D. (Age 56)
    Chief Technology Officer













TNYA Stock - Frequently Asked Questions

Should I buy or sell Tenaya Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tenaya Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TNYA shares.
View TNYA analyst ratings
or view top-rated stocks.

What is Tenaya Therapeutics' stock price forecast for 2023?

5 Wall Street research analysts have issued 1 year target prices for Tenaya Therapeutics' stock. Their TNYA share price forecasts range from $21.00 to $28.00. On average, they predict the company's stock price to reach $24.67 in the next twelve months. This suggests a possible upside of 958.7% from the stock's current price.
View analysts price targets for TNYA
or view top-rated stocks among Wall Street analysts.

How have TNYA shares performed in 2022?

Tenaya Therapeutics' stock was trading at $18.95 at the beginning of the year. Since then, TNYA shares have decreased by 87.7% and is now trading at $2.33.
View the best growth stocks for 2022 here
.

When is Tenaya Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our TNYA earnings forecast
.

How were Tenaya Therapeutics' earnings last quarter?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.20.

When did Tenaya Therapeutics IPO?

(TNYA) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

What is Tenaya Therapeutics' stock symbol?

Tenaya Therapeutics trades on the NASDAQ under the ticker symbol "TNYA."

Who are Tenaya Therapeutics' major shareholders?

Tenaya Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.90%), Price T Rowe Associates Inc. MD (5.11%), Regents of The University of California (3.93%), RA Capital Management L.P. (3.87%), Alphabet Inc. (2.21%) and State Street Corp (0.98%). Insiders that own company stock include Eli Casdin and Timothy Hoey.
View institutional ownership trends
.

How do I buy shares of Tenaya Therapeutics?

Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tenaya Therapeutics' stock price today?

One share of TNYA stock can currently be purchased for approximately $2.33.

How much money does Tenaya Therapeutics make?

Tenaya Therapeutics (NASDAQ:TNYA) has a market capitalization of $96.42 million. The company earns $-72,720,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

How many employees does Tenaya Therapeutics have?

The company employs 106 workers across the globe.

How can I contact Tenaya Therapeutics?

The official website for the company is www.tenayatherapeutics.com. The company can be reached via phone at 650-825-6900 or via email at investors@tenayathera.com.

This page (NASDAQ:TNYA) was last updated on 12/6/2022 by MarketBeat.com Staff